Information:
Error:
ID
18436
Description
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00193479
Link
https://clinicaltrials.gov/show/NCT00193479
Keywords
Versions (1)
- 11/4/16 11/4/16 -
Uploaded on
November 4, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-Hodgkins Lymphoma NCT00193479
Eligibility Non-Hodgkins Lymphoma NCT00193479
- StudyEvent: Eligibility
Similar models
Eligibility Non-Hodgkins Lymphoma NCT00193479
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Clinical Trial Eligibility Criteria Fulfill
Item
to be included in this study, you must meet the following criteria:
boolean
C1516637 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Diffuse Large B-Cell Lymphoma positive for CD20 antigen
Item
histologically documented large b-cell, cd20-positive non-hodgkin's lymphoma
boolean
C0079744 (UMLS CUI [1,1])
C0882818 (UMLS CUI [1,2])
C0882818 (UMLS CUI [1,2])
Prior Therapy
Item
no previous treatment
boolean
C1514463 (UMLS CUI [1])
Ann Arbor lymphoma staging system
Item
clinical stage ii, iii, or iv by the ann arbor staging criteria
boolean
C0432516 (UMLS CUI [1])
Age
Item
age > 70 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Bone Marrow function | Liver function | Renal function
Item
adequate bone marrow, liver and kidney function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Informed Consent
Item
must give written informed consent prior to entering this trial
boolean
C0021430 (UMLS CUI [1])
Clinical Trial Eligibility Criteria Fulfill
Item
you cannot participate in this study if any of the following apply to you:
boolean
C1516637 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Age
Item
age < 18 years
boolean
C0001779 (UMLS CUI [1])
Lymphoma Central Nervous System Involvement
Item
central nervous system involvement with lymphoma
boolean
C0024299 (UMLS CUI [1,1])
C4050309 (UMLS CUI [1,2])
C4050309 (UMLS CUI [1,2])
Malignant Neoplasm Treated
Item
coexistent active malignancies treated within five years
boolean
C0006826 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C1522326 (UMLS CUI [1,2])
Communicable Disease Excludes Combination Chemotherapy
Item
active infection precluding the use of combination chemotherapy
boolean
C0009450 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C1521750 (UMLS CUI [1,3])
C0332196 (UMLS CUI [1,2])
C1521750 (UMLS CUI [1,3])
HIV Infections
Item
hiv infection
boolean
C0019693 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Clinical Trial Eligibility Criteria Additional
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])